Companies / 1AI

ALGORAE PHARMACEUTICALS LIMITED

ASX:1AIPharmaceuticals, Biotechnology & Life Sciences
2.03B shares on issueASX (delayed) · as of 28 July 2026$0.013price · delayed$26.4Mmarket cap · indicative
C
Dilution grade

Share count grew 20% in 24 months; 3 cash raises in 24 months; options/rights overhang 64% of shares

Cash runway23.0 quarters of funding
Share-count growth (24m)20.2%
Raise cadence (24m)3 cash raises
Options & rights overhang63.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ALGORAE PHARMACEUTICALS LIMITED's ordinary share count grew 20.2% between May 2024 and July 2026 to 2.03B shares. The company raised capital three times in that period for total disclosed proceeds of A$4.3M, most recently via a Placement in June 2026. Options and rights on issue could convert into 1.29B new shares, equal to 63.8% of the current share count; none are in the money at the current share price and the nearest expiry is December 2029. At the March 2026 quarter the company reported A$9.0M in available cash, about 23.0 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
63.8%
Max option dilution
0.0%
ITM option dilution
3
Raises · last 12 months
23.0 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 2.03B per ASX (delayed) (28 July 2026).
1.76B1.86B1.96BDec 24Sept 25July 26Cash raise · 15 June 2026Cash raise · 1 Apr 2026Cash raise · 17 Nov 2025

Cash runway

23.0 qtrs
More than four quarters of funding at the recent spend rate.
$9.0M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
21 July 20263H · cancellation1AI : ORDINARY FULLY PAID2.03BAppendix 3H
6 July 20262A · quoted issue1AI : ORDINARY FULLY PAID2.03BAppendix 2A
19 June 20262A · quoted issue1AI : ORDINARY FULLY PAID2.03BAppendix 2A
19 June 20262A · quoted issue1AI : ORDINARY FULLY PAID2.02BAppendix 2A
25 May 20262A · quoted issue1AI : ORDINARY FULLY PAID2.02BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 3 in the last 12 months

—
Placement
15 June 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

63.8%
Total overhang · of current shares
0.0%
In the money · at current price
1.29B
Potential new shares
Dec 2029
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
5 Mar 2026DAVID HAINSWORTHOther313k—$4k3Y notice
22 Dec 2025DAVID HAINSWORTHOther25.6M3.1M—3Y notice
22 Dec 2025BRADLEY LATHAMOther20.0M4.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026Initial Director's Interest Notice - TV
21 July 2026Final Director's Interest Notice - BD
21 July 2026Notification of cessation of securities - 1AI
14 July 2026Nasdaq Pharma Chairman Troy Valentine Joins Algorae Board
6 July 2026Cleansing Notice
6 July 2026Application for quotation of securities - 1AI
2 July 2026$PPeter Mac Testing Validates AlgoraeOS v2
1 July 2026$PUpdated - NSW Health Public Hospital Supply Contract
30 June 2026$PAlgorae Awarded NSW Health Public Hospital Supply Contract
30 June 2026Company Secretary Appointment/Resignation
28 June 2026Algorae Named Launch Partner for Sovereign AI Initiative
24 June 2026Change of Auditor
19 June 2026Cleansing Notice
19 June 2026Application for quotation of securities - 1AI
19 June 2026Application for quotation of securities - 1AI
16 June 2026Proposed issue of securities - 1AI
25 May 2026Notification regarding unquoted securities - 1AI
25 May 2026Application for quotation of securities - 1AI
17 May 2026$PAlgorae Expands AI Drug Combination Pipeline
5 May 2026$P1AI Executes License & Supply Agreement with Torrent Pharma

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.